Last reviewed · How we verify
Pulmonary hypertension-specific therapy
At a glance
| Generic name | Pulmonary hypertension-specific therapy |
|---|---|
| Also known as | PH-specific therapy, PH-Targeted Medical Therapy |
| Sponsor | Irina E. Chazova |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension (PHASE3)
- A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) (PHASE3)
- Impact of Multi-Component Interventions on High-Risk COPD Smokers (NA)
- Exploration of Metabolome in Patients With Interstitial Lung Disease and Pulmonary Hypertension With or Without Specific Pulmonary Hypertension Treatment
- Impact on Physical Activity of Coronary Patients in Phase 3 of a Therapeutic Consolidation Educational Program Involving a "Patient Partner" Associated With a Healthcare Professional. (NA)
- Registry of Patients With chrOnic thromboemboLic Pulmonary hypErTension
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension (PHASE4)
- Association Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pulmonary hypertension-specific therapy CI brief — competitive landscape report
- Pulmonary hypertension-specific therapy updates RSS · CI watch RSS
- Irina E. Chazova portfolio CI